Study identifier:5077/9014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A functional magnetic resonance imaging study on the effect of an atypical antipsychotic (quetiapine) on blunted affect in schizophrenia.
schizophrenia
Phase 4
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
-
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|